Savara Inc(NASDAQ:SVRA) 
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Aus...
Website: http://www.savarapharma.com
Founded: 1995
Full Time Employees: 36
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 2.80
H 2.92
L 2.75
C 2.85
V 1,074,982
10EMA 2.85
20EMA 2.85
60EMA 2.85
120EMA 2.85
250EMA 2.85